360° SearchNetwork Hot Spots Trends Time Series

Solid Tumors

Type: Keyphrase

Name: Solid Tumors

First reported 23 hours ago - Updated 23 hours ago - 1 reports

Jennerex Biotherapeutics Raises $21.6M for Cancer Therapy

Jennerex Biotherapeutics Inc., which develops oncolytic immunotherapies for solid tumors, said it has raised $21.6 million in a private placement.Jennerex will use the capital to advance its lead product, Pexa-Vec, a potential treatment for liver, colorectal ... [Published Dow Jones Financial Information Services - 23 hours ago]

Entities: Jennerex Biotherapeutics Inc, Cancer, Pexa-Vec, oncolytic

First reported May 23 2013 - Updated May 23 2013 - 1 reports

NWBO: Great Progress Made to Advance DCVax-L and DCVax-Direct

By Grant Zeng, CFANWBO Reports First Quarter of 2013 FinancialsOn May 16, Northwest Biotherapeutics (NWBO) filed its 10-Q for the first quarter of 2013.There was no revenue for the first quarter of 2013.Research and development expense was $11.6 million ... [Published Yahoo! Finance - May 23 2013]

Entities: Tumor, Brain Cancer, Phase III

First reported May 23 2013 - Updated May 23 2013 - 2 reports

CytRx to Present at the Marcum MicroCap Conference Business Wire

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman will present at the 2nd Annual Marcum MicroCap Conference on Thursday, ... [Published Yahoo! Finance - May 23 2013]

Entities: CytRx Corporation, Clinical trials, doxorubicin, Oncology

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Jennerex Completes $21.6 Million Private Placement

Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it has completed a successful private ... [Published Zecco - May 23 2013]

Entities: Pexa-Vec, Jennerex Biotherapeutics Inc, Tumor, oncolytic

First reported May 23 2013 - Updated May 23 2013 - 1 reports

CytRx Q1 net loss decreases

3 minutes ago, 5:08am (ET) 05/23/2013 DatamonitorCytRx Corporation, a biopharmaceutical R&D company, has reported that net loss for the first quarter ended March 31, 2013 was $6.86 million, or $0.23 loss per share, compared to a net loss of $10.13 million, ... [Published Zecco - May 23 2013]

Entities: CytRx Corporation, soft tissue sarcoma, Solid Tumors

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Patent Issued for Methods, Compositions and Articles of Manu. . .

Patent Issued for Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of CancersSpectrum Pharmaceuticals, Inc.NewsRx.comBy a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Spectrum Pharmaceuticals, Inc. ... [Published Equities.com - May 22 2013]

Entities: Tumor, chemotherapeutic agent, agonist

First reported May 21 2013 - Updated May 22 2013 - 3 reports

CytRx Offers Initial Results from Trial with Aldoxorubicin i. . .

CytRx Offers Initial Results from Trial with Aldoxorubicin in Solid TumorsPaul QuintaroBenzingaCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and developmentcompany specializing in oncology, announced initial data from a Phase 1bclinical ... [Published Equities.com - May 21 2013]

Entities: CytRx Corporation, doxorubicin, Solid Tumors

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AM

Unknown AnalystGood morning, everyone. Thank you for coming to Day 2 of the UBS Healthcare Conference. My name is David Suki [ph]. I'm with the Healthcare Investment Banking team at UBS here in New York. It's my pleasure to introduce our next speaker, ... [Published Seeking Alpha - May 21 2013]

Entities: Adcetris, Patient, lymphoma, Seattle Genetics Inc, Drugs

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Chinese herb eradicates cancer in 40 days, says new research

by Jonathan Benson, staff writer(NaturalNews) The key to curing the type of pancreatic cancer that afflicted Apple visionary Steve Jobs just might be found in an ancient Chinese herb that has long played a crucial role in traditional Chinese medicine. ... [Published Natural News - May 22 2013]

Entities: Cancer, Tumor, Tripterygium wilfordii

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Medical Insight unveils new EasyViz release

-- Image and information management system developer Medical Insight has unwrapped version 5.0 of its EasyViz PACS software.To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below ... [Published Aunt Minnie - May 21 2013]

Entities: Solid Tumors, Enterprise, Metropolitan University

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Karyopharm Therapeutics raises $48.2M

PrintEmail Comments (0)Karyopharm Therapeutics Inc., a Natick-based biopharmaceutical company, said today it has raised $48.2 million in a second round of funding that will be used to advance the company’s pipeline of novel drug candidates for the treatment ... [Published Boston Herald - May 20 2013]

Entities: Karyopharm Therapeutics Inc, Solid Tumors, Delphi Ventures

First reported May 18 2013 - Updated May 18 2013 - 2 reports

Will ASCO Unlock Big Value in This Cancer Drug Class?

It's a 100% FREE Motley Fool service...There's little denying that Roche's (NASDAQOTH: RHHBY ) cancer wonder drug Avastin has been a godsend to cancer patients and investors alike.Avastin -- which the Food and Drug Administration has approved to treat ... [Published Motley Fool Discussion Boards - May 18 2013]

Entities: Avastin, Monoclonal Antibodies, Metastatic

Quotes

...These cells, as the Nature paper notes, are defined "on the basis of their ability to seed tumors in animal hosts, to self renew and to spawn differentiated progeny." CSC's certainly meet these standards; such cells create non-CSC tumor cells, and if left unchecked, can cause a tumor to regrow, even if the bulk of...

Successful Capital Raise, Data For Lead Candidate, And Small Float Are Opportunitites For Stemline [Published Seeking Alpha - 4 hours ago]

...According to news originating from Udine, Italy, by NewsRx correspondents, research stated, "Thymidine phosphorylase (TP) expression has been found to be elevated in various solid tumors where it is likely involved in mechanisms that regulate cell proliferation, apoptosis, and angiogenesis. Based on these properties, it is tempting to hypothesize a potential prognostic role of TP, suggesting that a high TP expression could predict a poor outcome."

Findings on Breast Cancer Reported by Researchers at University Hospital [Published NewsRX - 19 hours ago]

"Helen Heslop is a prime example of an Otago graduate who has gone on to achieve important advancements in knowledge that produce tangible benefits to our health and well-being" Professor Squire says

Otago honours leading physician-scientist Professor Helen Heslop [Published Noodls - 23 hours ago]

...which represents the third most deadly cancer in the world," stated Laurent Fischer, M D , president and chief executive officer of Jennerex. "The strong participation in this financing by our existing investors provides important validation of Pexa-Vec's clinical potential and their belief in our targeted oncolytic immunotherapy platform. We look forward to sharing data from the TRAVERSE PhasePhase 2b study that completed enrollment earlier this week."

Jennerex Completes $21.6 Million Private Placement [Published Zecco - May 23 2013]

More Content

sort by: Date \| Relevance
Accuray Presents Positive Data Zacks [Published Yahoo! Finance - 3 hours ago]
Why Immunotherapy Stocks Could Be Set for a Big... [Published Motley Fool Discussion Boards - 4 hours ago]
Successful Capital Raise, Data For Lead Candida... [Published Seeking Alpha - 4 hours ago]
Now Available: Ariad Pharmaceuticals, Inc. (ARI... [Published Live-PR.com - 15 hours ago]
Findings on Breast Cancer Reported by Researche... [Published NewsRX - 19 hours ago]
Otago honours leading physician-scientist Profe... [Published Noodls - 23 hours ago]
Jennerex Biotherapeutics Raises $21.6M for Canc... [Published Dow Jones Financial Information Services - 23 hours ago]
Lpath Initiates Dosing in First Proof-of-Concep... [Published I Stock Analyst - May 23 2013]
NWBO: Great Progress Made to Advance DCVax-L an... [Published Yahoo! Finance - May 23 2013]
CytRx to Present at the Marcum MicroCap Conference [Published EON: Enhanced Online News - May 23 2013]
CytRx to Present at the Marcum MicroCap Confere... [Published Yahoo! Finance - May 23 2013]
CYTRX CORPORATION: CytRx to Present at the Marc... [Published 4 Traders - May 23 2013]
Jennerex Completes $21.6 Million Private Placement [Published Zecco - May 23 2013]
Jennerex Completes $21.6 Million Private Placement [Published Marketwire - Breaking News Releases - May 23 2013]
CytRx Q1 net loss decreases [Published Zecco - May 23 2013]
Antitumor Activity of Tumor-Targeted RNA Replic... [Published Bionity.com - May 23 2013]
Strike Impacts Medical Services at UCSF [Published University of California, San Francisco - May 23 2013]
Researchers at Sophia Childrens Hospital Target... [Published Equities.com - May 22 2013]
Thrifty Merrimack developing new cancer drugs a... [Published Reuters - May 22 2013]
Celgene's Management Presents at 2013 UBS Globa... [Published Seeking Alpha - May 22 2013]
The Leukemia & Lymphoma Society, Valor Biothera... [Published Staten Island Live - May 22 2013]
Patent Issued for Acid-Labile Lipophilic Prodru... [Published Equities.com - May 22 2013]
Patent Issued for Methods, Compositions and Art... [Published Equities.com - May 22 2013]
Onconova Announces Presentation of Oral Rigoser... [Published Equities.com - May 22 2013]
Clinical Data on TetraLogic Pharmaceuticals’ Sm... [Published Business Wire - May 22 2013]
Clinical Data on TetraLogic Pharmaceuticals’ Sm... [Published Business Wire Health News - May 22 2013]
THLD, ONCY, IVAC Are Seasonally Ripe To Go Down... [Published Individual.com - May 22 2013]
Chinese herb eradicates cancer in 40 days, says... [Published Natural News - May 22 2013]
AML genome answers no longer MIA [Published Drug Discovery News - May 22 2013]
CytRx Offers Initial Results from Aldoxorubicin... [Published BioMedReports - May 22 2013]

Blogs

sort by: Date \| Relevance
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013] Filed under: Investing There's little denying that Roche 's cancer wonder drug Avastin has been a godsend to cancer patients and investors alike. Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer ...
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013] Johnson & Johnson ( NYSE:JNJ ): Closing price $87.45J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid ...
4 Healthcare Stock Stories For Thursday Investi... [Published Wall St. Cheat Sheet - May 16 2013] Johnson & Johnson ( NYSE:JNJ ): Closing price $87.45 J&J’s Janssen Biotech announced Thursday that the FDA has cleared Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have shown corticosteroid ...
Progression-Free Survival Data for Investigatio... [Published News from Kidney Cancer Association - May 16 2013] Nintedanib is being evaluated in various solid tumors – including advanced NSCLC, ovarian cancer, liver cancer (hepatic cell carcinoma), kidney cancer (renal cell carcinoma) and colorectal cancer. 05/16/2013 ...
Jennerex Announces Science Translational Medici... [Published News from Kidney Cancer Association - May 16 2013] Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced the publication of data demonstrating ...

Audio/Video

sort by: Date \| Relevance
FAST: Fiber-optic Array Scanning Technology fro... [Published innovationSRI - Feb 25 2013]

Press Releases

sort by: Date \| Relevance
CytRx to Present at the Marcum MicroCap Conference [Published EON: Enhanced Online News - May 23 2013]
Jennerex Completes $21.6 Million Private Placement [Published Marketwire - Breaking News Releases - May 23 2013]
Clinical Data on TetraLogic Pharmaceuticals’ Sm... [Published Business Wire - May 22 2013]
Clinical Data on TetraLogic Pharmaceuticals’ Sm... [Published Business Wire Health News - May 22 2013]
Jennerex Announces Completion of Enrollment in ... [Published Marketwire - Breaking News Releases - May 21 2013]